<p>Percentage of tumors with mutations in <i>KRAS</i>, <i>BRAF</i> or <i>NRAS</i> as reported in the COSMIC Database and this study.</p
The occurrence of specific mutations in (A) all tissues, (B) the pancreas, (C) the large intestine, ...
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tu...
A novel grading system based on the counting of poorly differentiated clusters (PDC) of neoplastic c...
<p>A. <i>PIK3CA</i> mutations. B. <i>KRAS</i> mutations. C. <i>NRAS</i> mutations. D. <i>BRAF</i> mu...
<p>Frequency and percentage of <i>KRAS</i> and <i>BRAF</i> mutations in normal (N), low-grade dyspla...
<p>Asterisks indicate those chromosome arms where significant differences (p<0.05) in the rate of CN...
IMPACT STATEMENT: These data represent the largest aggregation of BRAF mutations within a single cli...
<p>Correlation between percentage of KRAS mutation in tumor cells and disease control rate.</p
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tu...
<p>Panel A: KRAS mutations (codons12 & 13: n = 674; codon61: n = 672). Panel B: BRAF mutations (exon...
To identify the mutation rate of KRAS and BRAF in Chinese patients with colorectal carcinoma (CRC), ...
A novel grading system based on the counting of poorly differentiated clusters (PDC) of neoplastic c...
Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessme...
Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessme...
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tu...
The occurrence of specific mutations in (A) all tissues, (B) the pancreas, (C) the large intestine, ...
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tu...
A novel grading system based on the counting of poorly differentiated clusters (PDC) of neoplastic c...
<p>A. <i>PIK3CA</i> mutations. B. <i>KRAS</i> mutations. C. <i>NRAS</i> mutations. D. <i>BRAF</i> mu...
<p>Frequency and percentage of <i>KRAS</i> and <i>BRAF</i> mutations in normal (N), low-grade dyspla...
<p>Asterisks indicate those chromosome arms where significant differences (p<0.05) in the rate of CN...
IMPACT STATEMENT: These data represent the largest aggregation of BRAF mutations within a single cli...
<p>Correlation between percentage of KRAS mutation in tumor cells and disease control rate.</p
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tu...
<p>Panel A: KRAS mutations (codons12 & 13: n = 674; codon61: n = 672). Panel B: BRAF mutations (exon...
To identify the mutation rate of KRAS and BRAF in Chinese patients with colorectal carcinoma (CRC), ...
A novel grading system based on the counting of poorly differentiated clusters (PDC) of neoplastic c...
Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessme...
Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessme...
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tu...
The occurrence of specific mutations in (A) all tissues, (B) the pancreas, (C) the large intestine, ...
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tu...
A novel grading system based on the counting of poorly differentiated clusters (PDC) of neoplastic c...
DOI
Add to ORKG